Ciclesonide, administered once daily, has a low incidence of oropharyngeal adverse events in pediatric asthma patients

Abstract

RATIONALE: Use of inhaled corticosteroids (ICS) is associated with local oropharyngeal adverse events that can negatively impact treatment initiation and adherence. Ciclesonide (CIC) delivered via hydrofluoroalkane metered-dose inhaler is a new, effective ICS with low oral deposition (<1%) and high lung deposition (~52%). CIC is primarily converted in the lung to its active metabolite, desisobutyryl-ciclesonide (des-CIC). Des-CIC has high serum protein binding and high glucocorticoid receptor affinity.